SLC30A8 and Hyperglycemia: Because of its known function, the initial hypothesis was that reduced ZnT8 activity would increase risk of T2D [72, 73]; however, when numerous Slc30a8 knockout mice were subsequently created and tested for a variety of glycemic phenotypes, no consistent effects on hyperglycemia emerged [73–77].